Skip to main content
Premium Trial:

Request an Annual Quote

PPO MultiPlan Covering GenomeDx's Prostate Cancer Test

NEW YORK (GenomeWeb) – Prostate cancer diagnostics firm GenomeDx today announced it has signed a contract with MultiPlan for diagnostic laboratory testing.

As result of the deal, members of the preferred provider organization will have access to GenomeDx's Decipher Prostate Cancer Classifier, which measures a patient's biological risk of developing metastatic prostate cancer. MultiPlan has more than 500,000 providers in its network.

In June, GenomeDx and Prime Health Services inked a deal providing coverage for Decipher, and more than 190 million covered lives now have access to GenomeDx's test, the San Diego-based company said.

Decipher uses whole-genome analysis to profile RNA expression signatures to measure the aggressiveness of prostate cancer in patients who have had a prostatectomy. The test provides information that is distinct from PSA information and other clinical risk factors.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.